INFECTION/MICROBIOLOGY

(454) Relationships between Inflammation and Bacterial Ecology in BALF from the Cystic Fibrosis Airway

(455) Impaired recruitment of CCR2⁺ monocytes does not compromise host-defense against pulmonary Pseudomonas aeruginosa infections

(456) Staphylococcus aureus small colony variant infection pathology in the cystic fibrosis rat lung

(458) Mycobacterium avium adapts during chronic cystic fibrosis infection through increased mutation rates leading to the acquisition of antibiotic resistance

(459) Pseudomonas aeruginosa interaction with host-derived sphingosine

(460) Achromobacter xylosoxidans as a Cystic Fibrosis Related Pathogen

(463) Psl glycosyl hydrolase (PslGh) improves eradication of CF Pseudomonas aeruginosa biofilms when combined with antibiotics

(464) Impact of Elexacaftor/Tezacaftor/Ivacaftor on the Sinonasal Microbiome

(465) A Breath Test for P. aeruginosa? The Results Look Promising…

(466) Connecting the Genome and Volatiome In Pseudomonas aeruginosa Cystic Fibrosis Lung Infection Isolates

(468) Complement Opsonization Promotes Efficient Mycobacterium avium Killing by Human Neutrophils

(469) Epidemiology and clinical outcomes of airway infection with Pseudomonas species other than P. aeruginosa in cystic fibrosis

(470) The role of cloaking antibodies in Burkholderia cepacia complex lung infections

(471) Implications of nanobody-mediated inhibition of the Pseudomonas virulence factor Cif

(472) Synergistic Silver-Tobramycin Nanocomplexes Curtail Pseudomonas Lung Infections in CF Mouse Models.

(473) Acetate and propionate metabolism by Pseudomonas aeruginosa contributes to significant sinus inflammation in a rabbit model of sinusitis

(474) Inhibition of the envelope stress response in Pseudomonas aeruginosa is required for bacterial viability

(476) RNase E: A New Player in Pseudomonas aeruginosa Nutritional Virulence

(477) Longitudinal population genetics of Pseudomonas aeruginosa isolated from the sinuses, throat, and sputum of adults with cystic fibrosis

(478) Evaluation of Bacterial Detection by Microbial Cell Free DNA Using Plasma Collected During Admission for CF Pulmonary Exacerbation

(479) Biofilm formation of Pseudomonas aeruginosa isolated after initiation of CFTR-modulator therapy

(480) Understanding P. aeruginosa aggregate interactions with the emerging pathogen A. fumigatus

(482) Fourier transform infrared spectroscopy (FT-IR) for strain typing of Burkholderia cepacia complex and/or monitoring of strain carriage in chronically infected patients with cystic fibrosis

(483) Describing the Oropharyngeal Microbiome in Pediatric Patients with Cystic Fibrosis Transmembrane Regulator Related Metabolic Syndrome.

(484) Change in pulmonary infections 12 months after elexacaftor/tezacaftor/ivacaftor introduction: Results from the Danish National Cystic Fibrosis Cohort

(485) Chronic sequelae of SARS-CoV-2 in the Scnn1b-Tg mouse model of CF lung disease.

(486) Genomic barcoding of Pseudomonas aeruginosa is a high-throughput technique for studying evolutionary dynamics with single-cell resolution.

(488) Chronic Pseudomonas aeruginosa infection in a cystic fibrosis in vitro model

(489) Cystic Fibrosis airway metabolites contribute to persistent pulmonary infection

(490) Evaluation of the Biofire Filmarray Pneumonia panel plus for diagnosis of lower respiratory tract infections of cystic fibrosis transplanted patients

(491) Pel Overexpression by Pseudomonas Aeruginosa Reduces Induction of Heme-Oxygenase 1 in Macrophages.

(493) Bacterial and viral upper and lower airways infection in cystic fibrosis patients with stable condition

(494) Bacteriophage Distribution on Aerosolized Particles

(496) CFTR modulators restore autophagic-dependent bacterial clearance by improving the acidification of autophagolysosomes of F508del macrophages

(498) CFTR Modulator Therapy Increases Viral Mobility in Primary CF Airway Cultures Infected with RSV

(500) Immunoglobulins in Saliva as a Culture-Independent Marker of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

(501) Investigating the activity of pravibismane against bacterial isolates common in cystic fibrosis pulmonary infections

(504) Pseudomonas aeruginosa populations in synthetic cystic fibrosis media evolve cooperative behavior in response to cefiderocol pressure

(506) Antiviral response and ROS signaling triggers Warburg Effect and stimulates Pseudomonas aeruginosa (Pa) biofilm growth

(507) PHASE 1/2a RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY: SAFETY, PK, AND EFFICACY OUTCOME MEASURES OF INHALED GALLIUM CITRATE (AR-501) IN CYSTIC FIBROSIS PATIENTS

(508) The lack of IL-17 receptor C limits host resistance and sustains type 17 inflammation during airway chronic infections by Pseudomonas aeruginosa

(510) Prevalence and Clinical Impact of Respiratory Viral Infections in the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations

(512) A PhoRP-regulated pilin in Mycobacterium abscessus is required for association with and survival in macrophages and CF mice

(513) Unravelling the pathogenicity of Mycobacterium abscessus clinical isolates in CF pulmonary epithelial cell and mouse models of respiratory infection

(516) Cystic fibrosis sputum attenuates killing of Staphylococcus aureus by neutrophils by impairing phagolysosome fusion

(518) A targeted sequencing panel simultaneously detects Pseudomonas aeruginosa and Staphylococcus aureus species and antimicrobial resistance profiles from sputum

(519) Interactions Between Mycobacterium abscessus Dominant Circulating Clones Recovered from People with Cystic Fibrosis and Alveolar Macrophages from Healthy Donors

(520) Molecular evidence for Mycobacterium abscessus in NTM patient cohorts classified by sputum culture

(521) Understanding how nutrient availability impacts biofilm formation of nontuberculous mycobacterium (NTM)

(522) Random Mutagenesis Libraries to Define Interactions between M. abscessus and Therapeutic Phages

(523) Evolution of aminoglycoside resistance in chronic P. aeruginosa infections in the CF lung

(524) Striking a BAL-NS : combining metagenomics with culture methods shows nasal swabs to be a good proxy for broncho-alveolar lavage in microbial / pathogen surveillance

(525) Antimicrobial peptides and filamentous bacteriophages have opposing effects on sputum antibiotic penetration

(526) Pulmonary ketogenesis promotes tolerance to P. aeruginosa infection in the CF lung

(527) A paradoxical role of antibodies to Pseudomonas aeruginosa in cystic fibrosis chronic pulmonary infections

(528) Linking CFTR modulators to opportunistic bacterial infections in cystic fibrosis

(529) Stop bugging me; Auditing current inpatient nebuliser cleaning practise against hospital guidelines

(531) Developing Nebulized Phage Therapy for Chronic Pseudomonas aeruginosa Pulmonary Infections in Cystic Fibrosis (CF) Patients

(532) Humoral and cell-mediated responses to BNT162b2 mRNA vaccine against SARS-CoV-2 in people with cystic fibrosis

(533) Small molecule interference of the Pseudomonas aeruginosa glyoxylate pathway

(534) Covid-19 in cystic fibrosis patients compared to the general population: severity and virus-host cell interactions

(536) Not only 5bp-deletions in the intergenic region of the ica operon, but also mutations in icaR Staphylococcus aureus residing in the airways of people with cystic fibrosis

(537) GM-CSF is Essential for Effective Macrophage Killing of Nontuberculous Mycobacteria

(538) Monoclonal Antibodies Targeting Psl and PcrV Potentiate Bacterial Clearance of Pseudomonas aeruginosa from Cystic Fibrosis Children that Failed Eradication Therapy

(539) Single Sequential Bacteriophage Therapy Decreases Pseudomonas Virulence in Cystic Fibrosis Compared to a Cocktail Approach

(540) Developing a murine model for lung infection in cystic fibrosis that reflects Pseudomonas aeruginosa infection dynamics in the CF lung

(541) Effect of therapeutic antibiotic exposure on the oropharyngeal and fecal microbiota in infants with cystic fibrosis

(542) Genomic diversity of nontypeable Haemophilus influenzae impacts colonization and persistence in vivo

(543) Influence of nutrient availability in the cystic fibrosis airways on Staphylococcus aureus growth

(546) Therapeutic Beta-lactam Dosages and Broad-spectrum Antibiotics are Associated with Short-term Reductions in Microbial Richness and Beta-diversity

(547) Healthcare-Associated Links in Transmission of Nontuberculous mycobacteria in People with Cystic Fibrosis (HALT NTM): A Multi-Center Study

(548) A locus near ICOS is a genetic modifier for risk of Mycobacterium avium complex airway infection in persons with cystic fibrosis.

(550) A safe inhaled alkaline medication that alters airway pH in cystic fibrosis and inhibits RSV respiratory infection

(553) Determinants of LasR mutant Pseudomonas aeruginosa phagocytosis resistance

(554) Development of a Cystic Fibrosis Specific Antibiogram Evaluating Antimicrobial Susceptibility and Resistance Patterns amongst Pediatric, Adolescent, and Young Adult Patients

(555) Effectiveness of a Dedicated Pseuodomonas aeruginosa Eradication Care Process Model

(556) Evaluation of total bacterial 16S load and inflammation during IV-treated PEx in infrequent and frequent exacerbators

(557) Identifying the Ideal Mesenchymal Stem Cell Phenotype for Treating Cystic Fibrosis Lung Infection and Inflammation

(559) Inhaled antibiotics and resistance patterns in pediatric patients with cystic fibrosis: A retrospective, single-center study

(560) Keratan sulfate decoration on airway epithelial surfaces and its role in host defense and infections

(562) Low-frequency ultrasound significantly increases inactivation efficiency in Pseudomonas aeruginosa biofilms

(563) Novel Porphyrin Targets Biofilm, Pseudomonas aeruginosa, and Staphylococcus aureus

(564) Regional lung sampling after elexacaftor/tezacaftor/ivacaftor reveals Pseudomonas aeruginosa persistence in high and low damage segments

(566) Repurposing antimalarials drugs for the treatment of NTM infections

(569) Use of anti-P. aeruginosa antibodies and characterization of P. aeruginosa isolates for early antibiotic treatment monitoring

(570) Visualization of Pseudomonas aeruginosa biofilms in sputum of children with cystic fibrosis who fail eradication therapy